Cargando…

The brain protection of MLKL inhibitor necrosulfonamide against focal ischemia/reperfusion injury associating with blocking the nucleus and nuclear envelope translocation of MLKL and RIP3K

Mixed lineage kinase like protein (MLKL) is a key mediator of necroptosis. While previous studies highlighted the important role of MLKL as one of the central regulators of brain damage against acute ischemic neuronal injury, how the activation of MLKL mediates brain injuries and cell death remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xian-Yong, Lin, Bo, Chen, Wei, Cao, Rui-Qi, Guo, Yi, Said, Ali, Khan, Taous, Zhang, Hui-Ling, Zhu, Yong-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642205/
https://www.ncbi.nlm.nih.gov/pubmed/37964865
http://dx.doi.org/10.3389/fphar.2023.1157054
_version_ 1785146917424988160
author Zhou, Xian-Yong
Lin, Bo
Chen, Wei
Cao, Rui-Qi
Guo, Yi
Said, Ali
Khan, Taous
Zhang, Hui-Ling
Zhu, Yong-Ming
author_facet Zhou, Xian-Yong
Lin, Bo
Chen, Wei
Cao, Rui-Qi
Guo, Yi
Said, Ali
Khan, Taous
Zhang, Hui-Ling
Zhu, Yong-Ming
author_sort Zhou, Xian-Yong
collection PubMed
description Mixed lineage kinase like protein (MLKL) is a key mediator of necroptosis. While previous studies highlighted the important role of MLKL as one of the central regulators of brain damage against acute ischemic neuronal injury, how the activation of MLKL mediates brain injuries and cell death remains unclear, especially in astrocytes. In a transient middle cerebral artery occlusion (tMCAO) rat model in vivo, and an oxygen-glucose deprivation and reoxygenation (OGD/Re) injury model in both primary cultured astrocytes and human astrocytes, we show that necrosulfonamide (NSA), a MLKL specific inhibitor, reduces infarction volume and improves neurological deficits in tMCAO-treated rats. In addition, NSA treatment, as well as RIP1K inhibitor Nec-1 or RIP3K inhibitor GSK-872 treatment, decreases the OGD/Re-induced leakage of LDH in both primary cultured astrocytes and human astrocytes. NSA treatment also reduces the number of propidium iodide (PI)-positive cells, and prevents the upregulation of necroptotic biomarkers such as MLKL/p-MLKL, RIP3K/p-RIP3K, and RIP1K/p-RIP1K in ischemic penumbra of cerebral cortex in tMCAO-treated rats or in OGD/Re-treated human astrocytes. Importantly, NSA treatment blocks both the nucleus and nuclear envelope localization of MLKL/p-MLKL and RIP3K/p-RIP3K in ischemic cerebral cortex induced by tMCAO. Similarly, Co-immunoprecipitation assay shows that NSA treatment decreases tMCAO- or OGD/Re- induced increased combination of MLKL and RIP3K in nuclear envelope of ischemic penumbra of cerebral cortex or of primary cultured astrocytes, respectively. RIP3K inhibitor GSK-872 also reduces tMCAO-induced increased combination of MLKL and RIP3K in nuclear envelope of ischemic penumbra of cerebral cortex. These data suggest NSA exerts protective effects against focal ischemia/reperfusion injury via inhibiting astrocytic necroptosis through preventing the upregulation of necroptotic kinases as well as blocking both the nucleus and nuclear envelope co-localization of p-MLKL and p-RIP3K. The translocation of p-MLKL, along with p-RIP3K, to the nuclear envelope and the nucleus may play a crucial role in MLKL-mediated necroptosis under ischemic conditions.
format Online
Article
Text
id pubmed-10642205
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106422052023-11-14 The brain protection of MLKL inhibitor necrosulfonamide against focal ischemia/reperfusion injury associating with blocking the nucleus and nuclear envelope translocation of MLKL and RIP3K Zhou, Xian-Yong Lin, Bo Chen, Wei Cao, Rui-Qi Guo, Yi Said, Ali Khan, Taous Zhang, Hui-Ling Zhu, Yong-Ming Front Pharmacol Pharmacology Mixed lineage kinase like protein (MLKL) is a key mediator of necroptosis. While previous studies highlighted the important role of MLKL as one of the central regulators of brain damage against acute ischemic neuronal injury, how the activation of MLKL mediates brain injuries and cell death remains unclear, especially in astrocytes. In a transient middle cerebral artery occlusion (tMCAO) rat model in vivo, and an oxygen-glucose deprivation and reoxygenation (OGD/Re) injury model in both primary cultured astrocytes and human astrocytes, we show that necrosulfonamide (NSA), a MLKL specific inhibitor, reduces infarction volume and improves neurological deficits in tMCAO-treated rats. In addition, NSA treatment, as well as RIP1K inhibitor Nec-1 or RIP3K inhibitor GSK-872 treatment, decreases the OGD/Re-induced leakage of LDH in both primary cultured astrocytes and human astrocytes. NSA treatment also reduces the number of propidium iodide (PI)-positive cells, and prevents the upregulation of necroptotic biomarkers such as MLKL/p-MLKL, RIP3K/p-RIP3K, and RIP1K/p-RIP1K in ischemic penumbra of cerebral cortex in tMCAO-treated rats or in OGD/Re-treated human astrocytes. Importantly, NSA treatment blocks both the nucleus and nuclear envelope localization of MLKL/p-MLKL and RIP3K/p-RIP3K in ischemic cerebral cortex induced by tMCAO. Similarly, Co-immunoprecipitation assay shows that NSA treatment decreases tMCAO- or OGD/Re- induced increased combination of MLKL and RIP3K in nuclear envelope of ischemic penumbra of cerebral cortex or of primary cultured astrocytes, respectively. RIP3K inhibitor GSK-872 also reduces tMCAO-induced increased combination of MLKL and RIP3K in nuclear envelope of ischemic penumbra of cerebral cortex. These data suggest NSA exerts protective effects against focal ischemia/reperfusion injury via inhibiting astrocytic necroptosis through preventing the upregulation of necroptotic kinases as well as blocking both the nucleus and nuclear envelope co-localization of p-MLKL and p-RIP3K. The translocation of p-MLKL, along with p-RIP3K, to the nuclear envelope and the nucleus may play a crucial role in MLKL-mediated necroptosis under ischemic conditions. Frontiers Media S.A. 2023-10-24 /pmc/articles/PMC10642205/ /pubmed/37964865 http://dx.doi.org/10.3389/fphar.2023.1157054 Text en Copyright © 2023 Zhou, Lin, Chen, Cao, Guo, Said, Khan, Zhang and Zhu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhou, Xian-Yong
Lin, Bo
Chen, Wei
Cao, Rui-Qi
Guo, Yi
Said, Ali
Khan, Taous
Zhang, Hui-Ling
Zhu, Yong-Ming
The brain protection of MLKL inhibitor necrosulfonamide against focal ischemia/reperfusion injury associating with blocking the nucleus and nuclear envelope translocation of MLKL and RIP3K
title The brain protection of MLKL inhibitor necrosulfonamide against focal ischemia/reperfusion injury associating with blocking the nucleus and nuclear envelope translocation of MLKL and RIP3K
title_full The brain protection of MLKL inhibitor necrosulfonamide against focal ischemia/reperfusion injury associating with blocking the nucleus and nuclear envelope translocation of MLKL and RIP3K
title_fullStr The brain protection of MLKL inhibitor necrosulfonamide against focal ischemia/reperfusion injury associating with blocking the nucleus and nuclear envelope translocation of MLKL and RIP3K
title_full_unstemmed The brain protection of MLKL inhibitor necrosulfonamide against focal ischemia/reperfusion injury associating with blocking the nucleus and nuclear envelope translocation of MLKL and RIP3K
title_short The brain protection of MLKL inhibitor necrosulfonamide against focal ischemia/reperfusion injury associating with blocking the nucleus and nuclear envelope translocation of MLKL and RIP3K
title_sort brain protection of mlkl inhibitor necrosulfonamide against focal ischemia/reperfusion injury associating with blocking the nucleus and nuclear envelope translocation of mlkl and rip3k
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642205/
https://www.ncbi.nlm.nih.gov/pubmed/37964865
http://dx.doi.org/10.3389/fphar.2023.1157054
work_keys_str_mv AT zhouxianyong thebrainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT linbo thebrainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT chenwei thebrainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT caoruiqi thebrainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT guoyi thebrainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT saidali thebrainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT khantaous thebrainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT zhanghuiling thebrainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT zhuyongming thebrainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT zhouxianyong brainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT linbo brainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT chenwei brainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT caoruiqi brainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT guoyi brainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT saidali brainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT khantaous brainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT zhanghuiling brainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k
AT zhuyongming brainprotectionofmlklinhibitornecrosulfonamideagainstfocalischemiareperfusioninjuryassociatingwithblockingthenucleusandnuclearenvelopetranslocationofmlklandrip3k